Profluent, an AI-first protein design company, has announced it has secured $150 million in new funding. This significant investment will support the company's mission to develop deep generative models for designing and validating novel, functional proteins, aiming to revolutionize biomedicine through advanced AI capabilities. Founded in 2022, Profluent is based in Emeryville, CA, and focuses on leveraging artificial intelligence to unlock new biological possibilities.
The company specializes in decoding the language of life with artificial intelligence to create proteins with specific therapeutic or industrial applications. This substantial capital infusion underscores investor confidence in Profluent's innovative approach to protein design and its potential to impact various sectors, from drug discovery to materials science. The funding round saw participation from leading investors including Spark Capital, Insight Partners, Air Street Capital, AIX Ventures, and Convergent Ventures, highlighting strong support for its vision.
Profluent plans to strategically deploy the newly raised capital to accelerate its research and development efforts, expand its team of AI and biology experts, and scale its computational and experimental platforms. These initiatives are crucial for advancing its proprietary AI models and increasing the throughput of its protein design and validation processes. The company aims to broaden the scope of its protein applications and move closer to bringing its designed proteins to market, addressing unmet needs in various industries.
This investment positions Profluent for significant growth as it continues to push the boundaries of AI-driven protein engineering. The company is focused on leveraging its technological advancements to unlock new possibilities in medicine and beyond, driving innovation in the biotechnology landscape and solidifying its role as a leader in the field.
.png&w=3840&q=75)
